Anterogen.Co.,Ltd. (065660.KQ)
KRW 16060.0
(-6.3%)
KRW 16060.0
(-6.3%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 19.98 Billion KRW | 15.25% |
| 2022 | 17.34 Billion KRW | -12.57% |
| 2021 | 19.83 Billion KRW | 50.98% |
| 2020 | 13.13 Billion KRW | -18.91% |
| 2019 | 16.2 Billion KRW | -64.29% |
| 2018 | 45.36 Billion KRW | 293.48% |
| 2017 | 11.52 Billion KRW | 721.17% |
| 2016 | 1.4 Billion KRW | -24.04% |
| 2015 | 1.84 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 6.4 Billion KRW | -67.96% |
| 2024 Q2 | 3.64 Billion KRW | -43.14% |
| 2023 Q2 | 16.24 Billion KRW | -11.7% |
| 2023 Q4 | 19.98 Billion KRW | -10.68% |
| 2023 FY | 19.98 Billion KRW | 15.25% |
| 2023 Q1 | 18.39 Billion KRW | 6.07% |
| 2023 Q3 | 22.37 Billion KRW | 37.78% |
| 2022 FY | 17.34 Billion KRW | -12.57% |
| 2022 Q4 | 17.34 Billion KRW | -2.57% |
| 2022 Q3 | 17.79 Billion KRW | -3.73% |
| 2022 Q1 | 19.88 Billion KRW | 0.27% |
| 2022 Q2 | 18.48 Billion KRW | -7.03% |
| 2021 Q4 | 19.83 Billion KRW | 10.83% |
| 2021 FY | 19.83 Billion KRW | 50.98% |
| 2021 Q3 | 17.89 Billion KRW | 4.13% |
| 2021 Q1 | 26.36 Billion KRW | 100.71% |
| 2021 Q2 | 17.18 Billion KRW | -34.82% |
| 2020 Q2 | 22.1 Billion KRW | 48.28% |
| 2020 Q3 | 23.34 Billion KRW | 5.62% |
| 2020 Q4 | 13.13 Billion KRW | -43.73% |
| 2020 FY | 13.13 Billion KRW | -18.91% |
| 2020 Q1 | 14.9 Billion KRW | -7.98% |
| 2019 Q3 | 27.06 Billion KRW | -12.84% |
| 2019 Q2 | 31.05 Billion KRW | -40.57% |
| 2019 Q1 | 52.25 Billion KRW | 15.18% |
| 2019 FY | 16.2 Billion KRW | -64.29% |
| 2019 Q4 | 16.2 Billion KRW | -40.14% |
| 2018 Q3 | 46.02 Billion KRW | 1.79% |
| 2018 Q4 | 45.36 Billion KRW | -1.43% |
| 2018 FY | 45.36 Billion KRW | 293.48% |
| 2018 Q1 | 11.75 Billion KRW | 1.96% |
| 2018 Q2 | 45.21 Billion KRW | 284.62% |
| 2017 Q3 | 11.56 Billion KRW | 614.2% |
| 2017 Q1 | 1.36 Billion KRW | -2.61% |
| 2017 Q2 | 1.61 Billion KRW | 18.46% |
| 2017 Q4 | 11.52 Billion KRW | -0.34% |
| 2017 FY | 11.52 Billion KRW | 721.17% |
| 2016 FY | 1.4 Billion KRW | -24.04% |
| 2016 Q1 | 1.64 Billion KRW | -11.11% |
| 2016 Q2 | 1.54 Billion KRW | -6.21% |
| 2016 Q4 | 1.4 Billion KRW | 22.99% |
| 2016 Q3 | 1.14 Billion KRW | -25.92% |
| 2015 Q4 | 1.84 Billion KRW | 0.0% |
| 2015 FY | 1.84 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 88.207% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -962.92% |
| BINEX Co., Ltd. | 75.68 Billion KRW | 73.593% |
| Bioneer Corporation | 80.61 Billion KRW | 75.206% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 85.275% |
| CrystalGenomics, Inc. | 97.82 Billion USD | 79.568% |
| Helixmith Co., Ltd | 73.55 Billion KRW | 72.828% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 98.131% |
| Medy-Tox Inc. | 137.14 Billion KRW | 85.426% |
| Peptron, Inc. | 16.36 Billion KRW | -22.101% |
| Amicogen, Inc. | 248.12 Billion KRW | 91.945% |
| Genexine, Inc. | 79.68 Billion KRW | 74.917% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | 31.73% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | 51.584% |
| ALTEOGEN Inc. | 108.25 Billion KRW | 81.538% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | 72.653% |
| SillaJen, Inc. | 19.4 Billion KRW | -3.019% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 88.84% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | 61.922% |
| Genomictree Inc. | 7.81 Billion KRW | -155.838% |
| MedPacto, Inc. | 9.56 Billion KRW | -108.941% |
| D&D Pharmatech | 23.98 Billion KRW | 16.672% |
| EASY BIO,Inc. | 105.86 Billion KRW | 81.121% |
| GI Innovation, Inc. | 9.63 Billion KRW | -107.413% |